Search for: "ACTAVIS" Results 561 - 580 of 1,006
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Jun 2014, 9:59 pm by Patent Docs
• Defendants: Actavis Laboratories FL Inc.; Actavis Inc.; Actavis Pharma Inc.; Watson Laboratories Inc. [read post]
20 Jun 2014, 7:58 pm by Aaron Barkoff
" Here is the complete agenda: Unearthing Changes at the Office of Generic Drugs and Understanding Their Impact on the Future Growth and Evolution of the Generic Drug Industry Deciphering GDUFA and Its Impact on ANDA Approvals, Profit Margins, and Performance Metrics Demystifying the FDA's Rulemaking Authority: Exploring How FDA's Proposed Labeling Rule and Other Proposed Rules and Guidances Will Affect the Dynamics of the Generic Pharmaceutical Industry The Changing Paradigm of the… [read post]
10 Jun 2014, 7:44 pm
 In this post, guest contributor Paul England (Taylor Wessing LLP) explains the legal issues and their consequences:UKIPO -- a 'court' for the purposes of the Brussels I Regulation Some courts look like this ...With Actavis v Eli Lilly [noted on the IPKat here] still fresh in our minds, and amendments to the Brussels I Regulation (recast) progressing through the European Parliament in preparation for the Unified Patent Court, jurisdictional matters are a hot topic… [read post]
10 Jun 2014, 5:25 pm by Lawrence B. Ebert
., Actavis, Inc., Watson Laboratories,Inc., and Watson Pharma, Inc. [read post]
9 Jun 2014, 2:28 pm
He filed a drug defect case against Teva and Actavis, which are the two companies that made the generic drugs he took, and Wyeth, the maker of Reglan. [read post]
9 Jun 2014, 11:25 am
Last month, as reported by the Los Angeles Times, the California counties of Orange and Santa Clara sued Actavis, Endo Health Solutions Inc., Johnson & Johnson's Janssen Pharmaceuticals, Purdue Pharma and Teva Pharmaceutical Industries' Cephalon Inc. for causing the national prescription drug epidemic. [read post]
22 May 2014, 3:58 pm by Aaron Barkoff
 Speakers include in-house counsel from Eli Lilly, Mylan, Sandoz, Amgen, AbbVie, Momenta, J&J, and Actavis. [read post]
18 May 2014, 5:30 am by Barry Sookman
The IPKat: There is (copyright) life on the planet of the APIs http://t.co/toitlR5Th2 -> Legal Theory Blog: Rub on Copyright Exhaustion (the First-Sale Doctrine) http://t.co/BpfMDEtcni -> Oracle vs. [read post]
17 May 2014, 5:30 am by Barry Sookman
Rogers explains why it came last in Netflix rankings http://t.co/c0tGfLBb6e -> Interes Actavis UK v Eli Lilly & Company [2014] EWHC 1511 http://t.co/1Cw5ucuStG – patent judgment dealing with multi-jurisdictional claims -> Appeal allowed- reasons to follow Canadian Artists’ Representation v. [read post]
16 May 2014, 9:45 pm by Patent Docs
The conference will provide optimal strategies to help attendees maximize their patent portfolios, including: • The radical SPC decisions in Georgetown University, Actavis and Eli Lilly; • Capitalise on second medical use patents by implementing proven strategies and utilising tactical enforcement and remedial methods; • Fundamental update on the imminent Unitary Patent and Unified Patent Court and how to adapt business strategies effectively; • The 'Right' to… [read post]
16 May 2014, 8:58 am
 So this moggy is enormously grateful to his EIP colleague Matthew Jones, for preparing a report of this case, which came out at the same time as the Actavis v Lilly decision. [read post]
15 May 2014, 11:40 am
 Although the claims also required other components, Actavis admitted that the product is to be administered in combination with vitamin B12 and folic acid (since Actavis intend to seek regulatory approval by reference to Lilly's product which is administered together with both vitamin B12 and folic acid), and so the infringement of other integers of the claim was not at issue. [read post]
13 May 2014, 9:23 am
"All this is compliant with the GAT and Folien decisions and the Corte di Cassazione ruling, as well the UK decision in Joined cases Actavis Group hf v Eli Lilly & Company (USA) and Medis ehf v Eli Lilly & Company (USA) [here]. [read post]
13 May 2014, 5:00 am by Gene Quinn
Actavis plc (NYSE: ACT) announced yesterday that it has entered into an agreement with Valeant Pharmaceuticals International (NYSE: VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya®... [read post]